Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, New Zealand.
Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Vaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Adv Drug Deliv Rev. 2021 Aug;175:113822. doi: 10.1016/j.addr.2021.05.032. Epub 2021 Jun 3.
Recently, there have been increasing numbers of publications illustrating the potential of light-based antimicrobial therapies to combat antimicrobial resistance. Several modalities, in particular, which have proven antimicrobial efficacy against a wide range of pathogenic microbes include: photodynamic therapy (PDT), ultraviolet light (UVA, UVB and UVC), and antimicrobial blue light (aBL). Using these techniques, microbial cells can be inactivated rapidly, either by inducing reactive oxygen species that are deleterious to the microbial cells (PDT, aBL and UVA) or by causing irreversible DNA damage via direct absorption (UVB and UVC). Given the multi-targeted nature of light-based antimicrobial modalities, it has been hypothesised that resistance development to these approaches is highly unlikely. Furthermore, with the exception of a small number of studies, it has been found that resistance to light based anti-infective agents appears unlikely, irrespective of the modality in question. The concurrent literature however stipulates, that further studies should incorporate standardised microbial tolerance assessments for light-based therapies to better assess the reproducibility of these observations.
最近，越来越多的文献表明，基于光的抗菌疗法具有对抗抗菌药物耐药性的潜力。几种模式，特别是已经证明对多种致病微生物具有抗菌功效的模式，包括：光动力疗法（PDT）、紫外线（UVA、UVB 和 UVC）和抗菌蓝光（aBL）。使用这些技术，微生物细胞可以通过诱导对微生物细胞有害的活性氧（PDT、aBL 和 UVA）或通过直接吸收（UVB 和 UVC）导致不可逆的 DNA 损伤来快速失活。鉴于基于光的抗菌模式的多靶向性质，人们假设对这些方法产生耐药性的可能性很小。此外，除了少数研究外，已经发现无论所涉及的模式如何，对基于光的抗感染剂的耐药性似乎不太可能。然而，相关文献还规定，应该进行进一步的研究，将基于光的疗法的标准化微生物耐受性评估纳入其中，以更好地评估这些观察结果的可重复性。
